Mengjie Liu

Mengjie Liu


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2018 in Cancer Science
Verified
Journal Article
Open access
PDF file
MLMengjie Liu
Mengjie Liu
LJLili Jiang
Lili Jiang
XFXiao Fu
Xiao Fu
WWWenjuan Wang
Wenjuan Wang
JMJiequn Ma
Jiequn Ma
XLXuan Liang
Xuan Liang
Liver kinase B1 (LKB1) as a tumor suppression gene that is associated with various kinds of cancers, including lung cancer. In this study, we found that the effect of LKB1 on tumor growth was dependent on its subcellular expression in A549 and HCC827 cells. Full‐length LKB1 decreased the proliferation and clonogenicity of A549‐LKB1 and HCC827‐LKB1 cells, but increased their apoptosis. Opposite effects were observed in A549‐LKB1s and HCC827‐LKB1S cells that overexpressed truncated LKB1 without the nuclear localization sequence. The truncated cytoplasmic LKB1 enhanced the growth of implanted tumors in vivo. The truncated cytoplasmic LKB1 promoted autophagy, which was independent of AMP‐activated protein kinase and mTOR signaling in A549 and HCC827 cells. Further characterization indicated that higher levels of cytoplasmic LKB1 expression were associated with advanced TNM stage and reduced overall survival (OS) in 190 patients with adenocarcinoma. In contrast, high nuclear expression of LKB1 is associated with early TNM stage and longer OS. The high level of cytoplasmic LKB1 expression was an independent risk factor for poor overall survival in patients with adenocarcinoma. Together, our results revealed that cytoplasmic LKB1 promotes the growth of lung adenocarcinoma and could be a prognostic marker for lung adenocarcinoma.

16 October 2021 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
MLMengjie Liu
Mengjie Liu
XFXiao Fu
Xiao Fu
LJLili Jiang
Lili Jiang
JMJiequn Ma
Jiequn Ma
XZXiaoqiang Zheng
Xiaoqiang Zheng
WWWenjuan Wang
Wenjuan Wang
Metastasis is the main cause of colon cancer‐related deaths. RBP‐Jκ is involved in colon cancer development, but its function in colon cancer metastasis is still unclear. Tumour‐associated macrophages are the main cell components in tumour microenvironments. Here, we aimed to determine the function of RBP‐Jκ in colon cancer metastasis and its underlying mechanisms for modulating interactions between colon cancer cell and tumour‐associated macrophages. Through bioinformation analysis, we found that RBP‐Jκ was overexpressed in colon cancer tissues and associated with advanced colon cancer phenotypes, macrophage infiltration and shorter survival overall as confirmed by our patients’ data. And our patients’ data show that RBP‐Jκ expression and tumour‐associated macrophages infiltration are associated with colon cancer metastasis and are independent prognostic factors for colon cancer patients. Tumour‐associated macrophages induced colon cancer cell migration, invasion and epithelial‐mesenchymal transition through secreting TGF‐β1. Colon cancer cells with high RBP‐Jκ expression induced the expression of TGF‐β1 in tumour‐associated macrophages by secreting CXCL11. Our research revealed that colon cancer cells secreted CXCL11 via overexpression of RBP‐Jκ to enhance the expression of TGF‐β1 in tumour‐associated macrophages to further promote metastasis of colon cancer cells.

1 April 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
YLYanlin Li
Yanlin Li
HGHui Guo
Hui Guo
MLMengjie Liu
Mengjie Liu
ZZZehui Zhu
Zehui Zhu
HQHui Qiao
Hui Qiao
LJLili Jiang
Lili Jiang
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used medications in non-small cell lung cancer (NSCLC). We comprehensively evaluated the effect of NSAID exposure patterns on immunotherapy outcomes, prostaglandin E2 (PGE2) and immune cells. Methods: This multicenter study employed both prospective and retrospective approaches for patient enrollment. Patients were included if they had advanced NSCLC, and were first-time users of immune checkpoint inhibitor (ICI). Endpoints included progression-free survival (PFS) and overall survival (OS). Serum and tumor tissue were collected in the prospective subset for PGE2 and immune cell assay. Results: A total of 1,748 patients were included, with 232 patients prospectively enrolled. After multivariable adjustment, NSAID use was independently associated with improved PFS (HR 0.72, 95% CI 0.58 to 0.91, p=0.0053) and OS (HR=0.76, 95% CI 0.58 to 0.98, p=0.0364). Benefit was observed for both before-ICI (HR 0.75, 95 % CI 0.57 to 0.99, p=0.0383) and after-ICI initiation (HR 0.63, 95% CI 0.43 to 0.92, p=0.0159). For aspirin, low-dose aspirin users had better PFS than non-users (HR 0.69, 95% CI 0.51 to 0.94, p=0.0191), especially when used at least 30 days (HR=0.69, 95% CI 0.48 to 0.99, p=0.0464). Among non-selective NSAIDs, only after-ICI initiation improved OS (HR=0.49, 95% CI 0.24 to 0.99, p=0.0458). Any-grade (57.8% vs 53.4%) and grade ≥3 adverse events (9.2% vs 9.8%) were comparable among NSAID users and non-users. Serum sample indicated that aspirin was associated with less PGE2, which was related to better outcomes. On immune cells, RNA-seq revealed a correlation between the cyclooxygenase-2 pathway and neutrophils. Biosample analysis further demonstrated that aspirin use was associated with decreased neutrophils in both circulation and tumor. Conclusions: Long-term low-dose aspirin enhanced immunotherapy efficacy in patients with advanced NSCLC. PGE2 and neutrophils represented potential biomarkers guiding NSAID-immunotherapy integration. Trial registration number: NCT05754983 .

1 May 2014
Verified
Journal Article
Closed access
QGQianqian Guo
Qianqian Guo
ZLZhiyan Liu
Zhiyan Liu
LJLili Jiang
Lili Jiang
THTinghua Hu
Tinghua Hu
DLDongFan Li
DongFan Li
KNKejun Nan
Kejun Nan

26 September 2025 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
YZYajuan Zhang
Yajuan Zhang
YLYanlin Li
Yanlin Li
YZYamin Zhang
Yamin Zhang
TZTian Zhang
Tian Zhang
MLMiao Li
Miao Li
MLMengjie Liu
Mengjie Liu
The long-term impact of COVID-19 on cancer patients receiving immune checkpoint inhibitors (ICIs) remained unknown. This study aimed to investigate the association between COVID-19 and long-term outcomes in ICIs-treated lung cancer patients. Three hundred eighty-one patients with advanced lung cancer who were treated with ICIs were enrolled and followed for at least 6 months in 10 medical centers in China during Omicron pandemic. The primary endpoints were overall survival (OS) and progression-free survival (PFS). Cox model with time-dependent covariate and landmark analysis were used. The multivariable analysis showed that patients with COVID-19 had significantly worse OS (HR: 2.59 [1.58–4.26], P < 0.001) and PFS (HR: 1.55 [1.02–2.35], P < 0.001). In landmark analyses, COVID-19 that occurred within 3 months after initiation of ICIs was found to be associated with shorter OS (HR: 3.40 [1.70–6.77], P = 0.001) and PFS (HR: 3.40 [1.70–6.77], P = 0.02). In subgroup analysis, both mild and severe COVID-19 were associated with shorter OS (mild, HR: 2.39 [1.33–4.29], P = 0.004; severe, HR 4.46 [2.39–8.33], P < 0.002) and PFS (mild, HR 1.71 [1.05–2.78], P = 0.03; severe, HR 3.32 [1.97–5.60], P < 0.002). Additionally, there were no significant differences in OS or PFS among patients with varying treatment delays. COVID-19 had a negative impact on the long-term outcomes of patients with lung cancer who received ICIs, particularly if the infection occurred during the first 3 months of ICIs treatment. These findings are crucial for addressing the COVID-19 epidemic and other respiratory infectious diseases.

12 December 2025 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
YXYong Xi
Yong Xi
CXChuan Xu
Chuan Xu
FYFan Ye
Fan Ye
MYMin Yuan
Min Yuan
CYChunlin Ye
Chunlin Ye
BYBentong Yu
Bentong Yu
Accurate delineation of pulmonary nodules in chest computed tomography (CT) is essential for early lung cancer diagnosis and treatment planning. However, voxel-wise segmentation methods often produce fragmented masks and inconsistent topology due to low contrast, anatomical variability, and imaging noise. We propose CoreFormer, a segmentation framework that models nodules through structural core anchoring and geodesic shape decoding. CoreFormer identifies the intrinsic topological core of each nodule and generates continuous boundaries guided by anatomy-aware geodesic paths. It is built upon a Swin Transformer backbone and a dual-branch decoder consisting of a Structural Core Predictor and a Context-Aware Shape Decoder, enhanced by Feature Manifold Regularization for discriminative feature learning. Extensive experiments on four public datasets-LIDC-IDRI, LNDb, Tianchi-Lung (MosMedData), and NSCLC-Radiomics-demonstrate that CoreFormer achieves state-of-the-art boundary accuracy and topological fidelity, offering robust and high-fidelity pulmonary nodule segmentation.